Final results of a phase 1 study of EP0031, a next generation selective RET inhibitor (SRI) in patients with SRI naïve or pretreated advanced RET-altered tumors

Authors
Category Primary study
Conference2025 ASCO Annual Meeting I
Year 2025
This article has no abstract
Epistemonikos ID: 3f90dba9cd51d4e816ed1c92df42267fee0c8274
First added on: Sep 03, 2025